These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 27677098

  • 1. Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Polman NJ, Uijterwaal MH, Witte BI, Berkhof J, van Kemenade FJ, Spruijt JW, van Baal WM, Graziosi PG, van Dijken DK, Verheijen RH, Helmerhorst TJ, Steenbergen RD, Heideman DA, Ridder R, Snijders PJ, Meijer CJ.
    Int J Cancer; 2017 Jan 15; 140(2):423-430. PubMed ID: 27677098
    [Abstract] [Full Text] [Related]

  • 2. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT, Dalen I, Hansen E, Loge JL, Dybdahl BM, Dirdal MB, Moltu P, Berland JM.
    Cancer Cytopathol; 2017 Apr 15; 125(4):283-291. PubMed ID: 27918650
    [Abstract] [Full Text] [Related]

  • 3. Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion.
    Koo YJ, Hahn HS, Lee IH, Lim KT, Lee KH, Kim HS, Kim TJ, Chun YK, Kim HS, Hong SR.
    Virchows Arch; 2013 Nov 15; 463(5):689-96. PubMed ID: 24081504
    [Abstract] [Full Text] [Related]

  • 4. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M, Gotlieb W, Gilbert L, Hemmings R, Behr MA, Franco EL, STAIN-IT Study Group.
    Int J Cancer; 2021 Jan 15; 148(2):492-501. PubMed ID: 32781481
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
    Tay TKY, Lim KL, Hilmy MH, Thike AA, Goh ST, Song LH, Hwang JSG, Mantoo S.
    Malays J Pathol; 2017 Dec 15; 39(3):257-265. PubMed ID: 29279588
    [Abstract] [Full Text] [Related]

  • 6. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
    Liu W, Gong J, Xu H, Zhang D, Xia N, Li H, Song K, Lv T, Chen Y, Diao Y, Jao J, Dai S, Zhao P, Yao Q.
    Diagn Cytopathol; 2020 Jul 15; 48(7):635-644. PubMed ID: 32275355
    [Abstract] [Full Text] [Related]

  • 7. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.
    Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, Alameda F, Keller T, Rehm S, Ridder R, PALMS Study Group.
    Cancer Cytopathol; 2015 Jun 15; 123(6):373-81. PubMed ID: 25891096
    [Abstract] [Full Text] [Related]

  • 8. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
    Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, Kommoss F, Löning T, Ordi J, Regauer S, Ridder R.
    Gynecol Oncol; 2011 Jun 01; 121(3):505-9. PubMed ID: 21420158
    [Abstract] [Full Text] [Related]

  • 9. [Significance of p16/Ki-67 double immunocytochemical staining in cervical cytology ASCUS, LSIL, and ASC-H].
    Wu Y, Zhao J, Hu J, Wu XW, Zhu LR.
    Zhonghua Fu Chan Ke Za Zhi; 2017 Nov 25; 52(11):734-739. PubMed ID: 29179267
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology.
    Peeters E, Wentzensen N, Bergeron C, Arbyn M.
    Cancer Cytopathol; 2019 Mar 25; 127(3):169-180. PubMed ID: 30811902
    [Abstract] [Full Text] [Related]

  • 11. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
    Uijterwaal MH, Witte BI, Van Kemenade FJ, Rijkaart D, Ridder R, Berkhof J, Balfoort-van der Meij GA, Bleeker MC, Snijders PJ, Meijer CJ.
    Br J Cancer; 2014 Mar 18; 110(6):1579-86. PubMed ID: 24518601
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.
    Ebisch RM, van der Horst J, Hermsen M, Rijstenberg LL, Vedder JE, Bulten J, Bosgraaf RP, Verhoef VM, Heideman DA, Snijders PJ, Meijer CJ, van Kemenade FJ, Massuger LF, Melchers WJ, Bekkers RL, Siebers AG.
    Mod Pathol; 2017 Jul 18; 30(7):1021-1031. PubMed ID: 28304400
    [Abstract] [Full Text] [Related]

  • 13. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, Balfoort-van der Meij GA, Ridder R, Snijders PJ, Meijer CJ.
    Int J Cancer; 2015 May 15; 136(10):2361-8. PubMed ID: 25345358
    [Abstract] [Full Text] [Related]

  • 14. Association between p16/Ki-67 dual stain cytology results prior to and 6 months after LLETZ treatment for CIN and the follow-up regimen three years after treatment: a retrospective cohort study.
    Packet B, Goyens J, Weynand B, Poppe W, Dewilde K.
    Arch Gynecol Obstet; 2024 Jul 15; 310(1):493-499. PubMed ID: 38806944
    [Abstract] [Full Text] [Related]

  • 15. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
    Wright TC, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, Ridder R.
    Gynecol Oncol; 2017 Jan 15; 144(1):51-56. PubMed ID: 28094038
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL, Chen W, Lei XQ, Qin Y, Wu ZN, Pan QJ, Zhang X, Chang BF, Zhang SK, Guo HQ, Qiao YL.
    Oncotarget; 2016 Apr 19; 7(16):21181-9. PubMed ID: 27029033
    [Abstract] [Full Text] [Related]

  • 17. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
    Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, Castle PE, Wood SN, Stiemerling E, Poitras N, Lorey T, Kinney W.
    Cancer Cytopathol; 2014 Dec 19; 122(12):914-20. PubMed ID: 25132656
    [Abstract] [Full Text] [Related]

  • 18. [Clinical value of p16INK4a immunocytochemistry in cervical cancer screening].
    Song FB, Du H, Xiao AM, Wang C, Huang X, Yan PS, Liu ZH, Qu XF, Belinson JEROMEL, Wu RF.
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov 25; 55(11):784-790. PubMed ID: 33228350
    [Abstract] [Full Text] [Related]

  • 19. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China.
    Liao GD, Sellors JW, Sun HK, Zhang X, Bao YP, Jeronimo J, Chen W, Zhao FH, Song Y, Cao Z, Zhang SK, Xi MR, Qiao YL.
    Int J Cancer; 2014 Apr 01; 134(7):1715-24. PubMed ID: 24105727
    [Abstract] [Full Text] [Related]

  • 20. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
    Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK, Wright TC.
    Int J Cancer; 2020 May 01; 146(9):2599-2607. PubMed ID: 31490545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.